Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Operating Leases (2019 - 2025)

Historic Operating Leases for Harvard Bioscience (HBIO) over the last 10 years, with Q3 2025 value amounting to $8.8 million.

  • Harvard Bioscience's Operating Leases rose 1257.5% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 1257.5%. This contributed to the annual value of $7.5 million for FY2024, which is 2140.1% up from last year.
  • Latest data reveals that Harvard Bioscience reported Operating Leases of $8.8 million as of Q3 2025, which was up 1257.5% from $8.4 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Operating Leases peaked at $9.2 million during Q1 2021, and registered a low of $5.8 million during Q1 2024.
  • Its 5-year average for Operating Leases is $7.7 million, with a median of $7.8 million in 2024.
  • As far as peak fluctuations go, Harvard Bioscience's Operating Leases tumbled by 1859.08% in 2024, and later soared by 5031.28% in 2025.
  • Harvard Bioscience's Operating Leases (Quarter) stood at $8.6 million in 2021, then fell by 14.06% to $7.4 million in 2022, then decreased by 16.27% to $6.2 million in 2023, then rose by 21.4% to $7.5 million in 2024, then rose by 16.97% to $8.8 million in 2025.
  • Its Operating Leases stands at $8.8 million for Q3 2025, versus $8.4 million for Q2 2025 and $8.6 million for Q1 2025.